Exelixis Development Agreements
9 Contracts & Agreements
- Amendment #3 dated May 29, 2018, to Cooperative Research and Development Agreement for Extramural-PHS Clinical Research by and between The U.S. Department of Health and Human... (Filed With SEC on February 22, 2019)
- Amendment #2 Cooperative Research and Development Agreement #11-1-00006 Clinical Development of Exelixis Inc.s Proprietary Cabozantinib (XL184), a MET and Vascular Endothelial... (Filed With SEC on February 27, 2017)
- Amendment #1 Cooperative Research and Development Agreement #11-1-00006 Clinical Development of Exelixis Inc.s Proprietary Cabozantinib (XL184), a MET and Vascular Endothelial... (Filed With SEC on February 27, 2017)
- PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR EXTRAMURAL-PHS CLINICAL RESEARCH (Filed With SEC on February 27, 2017)
- COMPENSATION INFORMATION FOR NON-EMPLOYEE DIRECTORS 2017 Cash Compensation for Non-Employee Directors Board of DirectorsRetainer Fee $25,000 Additional Chair Retainer Fee $30,000... (Filed With SEC on February 27, 2017)
- PRODUCT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BETWEEN SMITHKLINE BEECHAM CORPORATION DOING BUSINESS AS GLAXOSMITHKLINE AND EXELIXIS, INC. DATED AS OF OCTOBER 28, 2002 (Filed With SEC on August 6, 2013)
- COMPENSATION INFORMATION FOR NON-EMPLOYEE DIRECTORS Exelixis, Inc. 2013 Cash Compensation for Non-Employee Directors Board of DirectorsRetainer Fee $20,000 Additional Chair... (Filed With SEC on February 21, 2013)
- SECOND AMENDMENT TO THE PRODUCT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BETWEEN SMITHKLINE BEECHAM CORPORATION D/B/AGLAXOSMITHKLINE AND EXELIXIS, INC. DATED AS OF OCTOBER 28,... (Filed With SEC on August 5, 2008)
- AMENDED AND RESTATED RESEARCH AND DEVELOPMENT AGREEMENT among (Filed With SEC on August 9, 2005)